Persistence of an infectious form of SARS-CoV-2 post protease inhibitor treatment of permissive cells in vitro
Nair, M. S.; Luck, M. I.; Huang, Y.; Sabo, Y.; Ho, D. D.
Show abstract
Reports have described SARS-CoV-2 rebound in COVID-19 patients treated with nirmatrelvir, a 3CL protease inhibitor. The cause remains a mystery, although drug resistance, re-infection, and lack of adequate immune responses have been excluded. We now present virologic findings that provide a clue to the cause of viral rebound, which occurs in [~]20% of the treated cases. The persistence of an intermediary form of infectious SARS-CoV-2 was experimentally documented in vitro after treatment with nirmatrelvir or another 3CL protease inhibitor, but not with a polymerase inhibitor, remdesivir. This infectious intermediate decayed slowly with a half-life of [~]1 day, suggesting that its persistence could outlive the treatment course to re-ignited SARS-CoV-2 infection as the drug is eliminated. Additional studies are needed to define the nature of this viral intermediate, but our findings point to a particular direction for future investigation and offer a specific treatment recommendation that should be tested clinically.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo 96%
- The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication 95%
- The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses 94%
Similar papers in this journal
- The combination of GS-441524 (remdesivir) and ribavirin results in a potent antiviral effect against human parainfluenza virus 3 infection in human airway epithelial cell cultures and in a mouse infection model 95%
- SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies 94%
- Kite-shaped molecules block SARS-CoV-2 cell entry at a post-attachment step 94%
Similar papers in this journal
Similar papers in this journal
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 97%
- A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity 95%
- Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.